Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates
Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates
The prophylactic administration of factor IX (FIX) is considered the most effective treatment for haemophilia B. The inter-individual variability and complexity of the pharmacokinetics (PK) of FIX, and the rarity of the disease have hampered identification of an optimal treatment regimens. The recent introduction of extended half-life recombinant FIX molecules (EHL-rFIX), has prompted a thorough reassessment of the clinical efficacy, PK and pharmacodynamics of plasma-derived and recombinant FIX. First, using longer sampling times and multi-compartmental PK models has led to more precise (and favourable) PK for FIX than was appreciated in the past. Second, investigating the distribution of FIX in the body beyond the vascular space (which is implied by its complex kinetics) has opened a new research field on the role for extravascular FIX. Third, measuring plasma levels of EHL-rFIX has shown that different aPTT reagents have different accuracy in measuring different FIX molecules. How will this new knowledge reflect on clinical practice? Clinical decision making in haemophilia B requires some caution and expertise. First, comparisons between different FIX molecules must be assessed taking into consideration the comparability of the populations studied and the PK models used. Second, individual PK estimates must rely on multi-compartmental models, and would benefit from adopting a population PK approach. Optimal sampling times need to be adapted to the prolonged half-life of the new EHL FIX products. Finally, costs considerations may apply, which is beyond the scope of this manuscript but might be deeply connected with the PK considerations discussed in this communication.
1023-1030
Iorio, Alfonso
32c59f2e-f026-469e-bea2-4d44b35ae1bd
Fischer, Kathelijn
1903f9d2-61df-4798-903c-5e9929e56720
Blanchette, Victor
52424c49-e637-4ae9-9a4c-bebac4621303
Rangarajan, Savita
9a5e4c7e-55ba-4a3a-b5f6-f1e269d927c3
Young, Guy
a7d770f7-b217-4fe8-8051-7b88c7460f62
Morfini, Massimo
50fa1505-e256-4342-a266-9c55e4affe72
Iorio, Alfonso
32c59f2e-f026-469e-bea2-4d44b35ae1bd
Fischer, Kathelijn
1903f9d2-61df-4798-903c-5e9929e56720
Blanchette, Victor
52424c49-e637-4ae9-9a4c-bebac4621303
Rangarajan, Savita
9a5e4c7e-55ba-4a3a-b5f6-f1e269d927c3
Young, Guy
a7d770f7-b217-4fe8-8051-7b88c7460f62
Morfini, Massimo
50fa1505-e256-4342-a266-9c55e4affe72
Iorio, Alfonso, Fischer, Kathelijn, Blanchette, Victor, Rangarajan, Savita, Young, Guy and Morfini, Massimo
(2017)
Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates.
Thrombosis and Haemostasis, 117 (06), .
(doi:10.1160/TH16-12-0942).
Abstract
The prophylactic administration of factor IX (FIX) is considered the most effective treatment for haemophilia B. The inter-individual variability and complexity of the pharmacokinetics (PK) of FIX, and the rarity of the disease have hampered identification of an optimal treatment regimens. The recent introduction of extended half-life recombinant FIX molecules (EHL-rFIX), has prompted a thorough reassessment of the clinical efficacy, PK and pharmacodynamics of plasma-derived and recombinant FIX. First, using longer sampling times and multi-compartmental PK models has led to more precise (and favourable) PK for FIX than was appreciated in the past. Second, investigating the distribution of FIX in the body beyond the vascular space (which is implied by its complex kinetics) has opened a new research field on the role for extravascular FIX. Third, measuring plasma levels of EHL-rFIX has shown that different aPTT reagents have different accuracy in measuring different FIX molecules. How will this new knowledge reflect on clinical practice? Clinical decision making in haemophilia B requires some caution and expertise. First, comparisons between different FIX molecules must be assessed taking into consideration the comparability of the populations studied and the PK models used. Second, individual PK estimates must rely on multi-compartmental models, and would benefit from adopting a population PK approach. Optimal sampling times need to be adapted to the prolonged half-life of the new EHL FIX products. Finally, costs considerations may apply, which is beyond the scope of this manuscript but might be deeply connected with the PK considerations discussed in this communication.
This record has no associated files available for download.
More information
Accepted/In Press date: 8 March 2017
e-pub ahead of print date: 7 November 2017
Identifiers
Local EPrints ID: 442855
URI: http://eprints.soton.ac.uk/id/eprint/442855
ISSN: 0340-6245
PURE UUID: 7753b45a-2434-452e-a8ce-4b73cacd5428
Catalogue record
Date deposited: 29 Jul 2020 16:34
Last modified: 17 Mar 2024 04:02
Export record
Altmetrics
Contributors
Author:
Alfonso Iorio
Author:
Kathelijn Fischer
Author:
Victor Blanchette
Author:
Guy Young
Author:
Massimo Morfini
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics